Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

132.78 +1.53 (+1.17%)
Streaming Delayed Price Updated: 3:11 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
47 48 Next >
7 ‘AgeTech’ Stocks to Profit From the Booming Longevity Market
Aging is an inevitability, as much as we try to deny it. Under this context, these AgeTech stocks may prove quite relevant. 
Via InvestorPlace
Looking Into Abbott Laboratories's Recent Short Interest
 
Via Benzinga
Stock Market Continues To Rally; ASML, Netflix, Tesla, Intel Are Big Earnings Movers: Weekly Review
The S&P 500 and Dow Jones hit fresh record highs on Friday. 
Via Investor's Business Daily
Topics Stocks
World's Smallest Brain Stimulation Device For Movement Disorder: FDA Approved Abbott's Liberta RC DBS system
Abbott's Liberta RC DBS system, the world's smallest FDA-approved rechargeable deep brain stimulation device. With only 10 recharges a year, it's compatible with NeuroSphere Virtual Clinic, reducing... 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Abbott Laboratories
 
Via Benzinga
Earnings Preview For Abbott Laboratories
 
Via Benzinga
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
 
Via Benzinga
Abbott Laboratories on track for new highs in 2024
Abbott Laboratories is a solid dividend play whose underlying business is returning to growth after years of COVID-19 impact. 
Via MarketBeat
Stock Market Extends Record Highs, S&P 500 Hits 4,900 On Tech Rally, Microsoft's $3 Trillion Mark: What's Driving Markets Wednesday?
It’s a bullish day on Wall Street, with major U.S. large-cap indices reaching record highs, driven by broad-based rallies in tech-related stocks as investors continue to embrace the AI trade. 
Via Benzinga
Topics Artificial Intelligence Stocks
Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript
ABT earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
$100 Invested In Abbott Laboratories 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Abbott Laboratories Surpasses Q4 Sales Expectations, Despite Dip In COVID-19 Testing Demand
Abbott Laboratories exceeds expectations with Q4 sales of $10.24B, showcasing resilience despite softer demand for COVID-19 testing. CEO anticipates continued growth in 2024. 
Via Benzinga
Abbott Labs Skids On Light Earnings Guidance Despite Quarterly Sales Beat
Abbott beat sales expectations and earnings came in light for the fourth quarter. 
Via Investor's Business Daily
Abbott Laboratories Barely Hits Q4 Target With $1.19 EPS
Abbott Laboratories announces Q4 results with $10.24 billion in revenue and an EPS of $1.19. 
Via Talk Markets
Nasdaq, S&P 500 Futures Jump As Wall Street Eagerly Awaits Tesla's Q4 Earnings: Analyst Says Rally Broadening But Favors These Stocks
Earnings have served to mitigate early January's weakness, and sentiment appears to be upbeat going into Wednesday's session. 
Via Benzinga
Topics Stocks
Earnings Scheduled For January 24, 2024
Companies Reporting Before The Bell • Freeport-McMoRan (NYSE:FCX) is estimated to report quarterly earnings at $0.22 per share on revenue of $5.86 billion. 
Via Benzinga
Investor Optimism Improves Following Earnings Reports; S&P 500 Reaches Another High
The CNN Money Fear and Greed index showed a further increase in overall market sentiment, while the index remained in the "Greed" zone on Tuesday. U.S. stocks closed mixed on Tuesday, with the Dow... 
Via Benzinga
Topics Stocks
Netflix, Tesla And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Arterial Device-Focused Inari Medical Likely Acquisition Target, Shares Are Attractively Valued: Analyst
Inari Medical with strong position in venous thrombectomy. Buy-rated by Needham with a $72 target. Undervalued shares with an 88% gross margin and anticipated double-digit revenue growth. 
Via Benzinga
7 Safe-Haven Stocks to Protect Your Portfolio During a Recession
We may not be out of the woods yet, which means certain stable enterprises should be on your radar. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Johnson & Johnson's stock price is at a critical turning point
Johnson & Johnson's dividend is safe for 2024 and may include another increase for this Dividend King. Results suggest another solid quarter for medtech. 
Via MarketBeat
Topics Intellectual Property
Top Stocks To Watch As Earnings Approach
Several expansive companies are expected to post stellar quarterly growth when they report Q4 earnings on Wednesday, January 24. Here are a few top-rated stocks to consider as their quarterly results... 
Via Talk Markets
My 5 Top Dividend Stocks to Buy Hand Over Fist in 2024
These stocks may help you win in 2024 -- no matter what the market does. 
Via The Motley Fool
S&P 500, Nasdaq, Dow Jones Strike All-Time Highs Ahead Of Key Earnings This Week: What's Driving Markets Monday?
US stocks rise to record highs on strong earnings reports, with small caps outperforming. Dollar steady, gold down, oil up. Bitcoin tumbles. AMD, TSLA, ADM, GILD, WDC top movers. GE, AAPL, FB, AMZN,... 
Via Benzinga
Topics Stocks
Medtronic receives FDA approval for deep brain stimulation system
Medical device maker Medtronic PLC (NYSE: MDT) received U.S. FDA approval for its implantable medical device called the Percept PC Deep Brain Stimulation (DBS) 
Via MarketBeat
Tesla, Netflix, Intel Take Center Stage In Pivotal Q4 Earnings Week As S&P 500 Eyes Breaking New Highs
According to Factset, the fourth-quarter earnings season has had a weak start, with the percentage of S&P 500 companies reporting positive earnings surprises below average. 
Via Benzinga
Topics Stocks
Better Growth Stock: Abbott vs. AbbVie
These healthcare giants also offer investors the promise of increasing passive income. 
Via The Motley Fool
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said Uber Technologies, Inc. (NYSE: UBER) shares hit an all-time high on Thursda 
Via Benzinga
3 Dividend Kings For Yield And Growth
Dividend Kings are known for safe dividends and reliable long-term growth. 
Via Talk Markets
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
47 48 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.